Objectives. Meta-analysis of pregabalin trials in FM using company trial reports, which provide more detailed information about trials than published papers. FM is a common condition with a significant impact on quality of life.
Introduction
FM is surrounded by controversy regarding both its aetiology and its status as a disease entity. Preliminary genetic and neurobiological evidence exists supporting differences between FM patients and controls extending beyond subjective patient reports of pain and interference with daily living [1] . Candidate biomarkers that may help to identify susceptible individuals or parallel disease activity are emerging [2] .
FM is defined as widespread pain for >3 months with pain on palpation at 11 or more of 18 specified tender points [3] . There are often other symptoms, such as poor sleep, fatigue and depression [4] .
FM profoundly limits activities of daily living, comparable with extent to RA, and has a considerable effect on productivity [5, 6] . It is common, especially in women, with an all-age prevalence of 1-2%. The female to male ratio is 6:1 [7] .
No current pharmacological or non-pharmacological FM treatment is entirely satisfactory, with most of them producing moderate or substantial pain relief in a minority only [8] [9] [10] [11] . With 60/120 mg duloxetine, with the largest numbers of patients before pregabalin trials, only 37% had a substantial benefit of at least 50% pain relief [12] .
Pregabalin shares with gabapentin a novel high-affinity drug binding site, the calcium channel alpha 2 -delta subunit [13] , and was the first drug to be licensed by the FDA for FM. The use of pregabalin in FM has been assessed in five clinical trials. Based on these trials this article performs a meta-analysis with regard to efficacy and safety outcomes.
Methods
Pfizer supplied information from all randomized, doubleblind, placebo-controlled trials (RCTs) of pregabalin for FM that were completed by July 2008 as PDFs of company clinical trial reports. A protocol for the review and analysis was agreed upon beforehand.
Four RCTs were of 'classical' double-blind, placebocontrolled trial design (trials 105 [14] , 1056 [15] , 1077 [16] and 1100 [17] ) and one used enriched enrolment randomized withdrawal [fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM) trial, trial 1059] [18] . All the trials were approved by local ethics committees, with written consent obtained according to the Declaration of Helsinki. A PubMed literature search using pregabalin in title or abstract and restricted to RCTs revealed no additional studies.
Trial patients were at least 18 years old. Women were neither pregnant nor lactating and were either post-menopausal, surgically sterilized or using contraception. Patients had to meet the ACR criteria for FM and have pain scores of 540 mm on the 100-mm visual analogue scale (VAS) after stopping any relevant pain or sleep medication.
Important exclusion criteria were: severe pain due to other conditions, rheumatic diseases other than FM, active infections, untreated endocrine disorders, severe depression, active malignancy, being immuno-compromised, other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities.
Trials in neuropathic pain can vary in their degree of enrichment, with three levels defined [19] . Complete enriched enrolment would occur when all participants responded to the test drug or a closely related drug with a similar mechanism of action. Partial enriched enrolment is the exclusion from a study of previous non-responders to the study drug or a similar drug, but where not all participants were exposed. Non-enriched enrolment is when no statement of inclusion or exclusion of patients could be interpreted as enriching the population to drug responders. Partial enrichment has been shown not to affect results [19] , though effects of complete enrichment are less clear in pain studies [20] .
In the four classical design RCTs, patients were randomized under double-blind conditions to receive oral pregabalin of 150-600 mg/day, or placebo. In the FREEDOM trial, all patients initially received pregabalin and were titrated to a dose (300, 450 or 600 mg/day) according to need and tolerability in an open-label phase lasting for 6 weeks. Those who achieved at least 50% reduction in VAS pain score from open-label baseline and reported overall improvement on the patient global impression of change (PGIC) scale of 'much improved' or 'very much improved' were termed 'responders'. Responders then entered the double-blind phase. They were randomly assigned to either continue with pregabalin at that dose or receive placebo for 26 weeks. All trials conformed to good clinical practice guidelines.
Outcomes chosen for meta-analysis of the four classical design RCTs related to measurements of efficacy and adverse events. These included mean weekly pain scores, patients achieving at least 30 or 50% pain relief (30 and 50% responders) and patients reporting 'much' or 'very much' improvement in PGIC; these correspond with definitions of moderate or substantial benefit as defined by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group [21] . Other efficacy measurements included scores from the FM impact questionnaire (FIQ), MOS-sleep scale (MOS-sleep), mean sleep quality score, short-form 36 (SF-36), multidimensional assessment of fatigue (MAF) global index and the hospital anxiety and depression scale (HADS). An explanation of these outcome measurements is provided in a glossary (see supplementary data available at Rheumatology Online). Data for additional analgesic consumption, adverse events (any adverse event, serious adverse events, dizziness, nausea and somnolence), discontinuations (all-cause, lack of efficacy and adverse event) and weight gain, were also extracted.
Due of its enriched enrolment randomized withdrawal design the FREEDOM trial used time to loss of therapeutic response over a period of 26 weeks as its primary efficacy measurement. This was defined as having either <30% reduction in VAS pain scores compared with open-label baseline at two consecutive visits of the double-blind phase, or worsening of FM symptoms such that alternative treatment was necessary. Analyses of secondary end-points (PGIC, FIQ, MOS-sleep, MAF global index, HADS and SF-36 subscales) compared end-points between pregabalin and placebo patients during the double-blind phase.
Trials were scored for quality and validity using the Oxford Quality Scale and the Oxford Pain Validity Scale [22, 23] . To qualify for inclusion in this systematic review, trials had to be both randomized and double blinded.
Guidelines for quality of reporting of meta-analysis were followed where appropriate [24] . Outcomes from the four classical design RCTs were pooled in an intention-to-treat analysis (number of patients randomly assigned and receiving at least one dose of trial drug). Homogeneity tests and funnel plots, though commonly used in metaanalysis, were not used here because they have been found to be unreliable [25] [26] [27] . For dichotomous data, relative benefit or risk and number needed to treat or harm (NNTs or NNHs) were calculated with 95% CIs. Relative risk was calculated using a fixed effects model, with no statistically significant difference between treatments assumed when the 95% CI included unity [28] . To permit calculation of relative risk we added 0.5 to arms of trials in which at least one arm had no events. NNT (or NNH) was calculated by the method of Cook and Sackett [29] , using the pooled number of observations. Statistically significant differences between NNTs were www.rheumatology.oxfordjournals.org established using the z-test [30] 
Results

Trial characteristics
Details are given in Table 1 . Of the four classical design RCTs, three studies (trials 1056, 1077 and 1100) used non-enriched enrolment. One study (trial 105) used partial enriched enrolment. The FREEDOM trial fulfilled the criteria for complete enriched enrolment [19] . Across the trials, 3808 patients aged between 18 and 82 years were treated with pregabalin or placebo. In each trial, >90% of patients were women. The trials lasted for 8-32 weeks. Pregabalin doses were 150-600 mg/day. All trials scored 5/5 on the Oxford Quality Scale and 16/16 on the Oxford Pain Validity Scale [22, 23] .
Analysis of outcomes
For our meta-analysis of efficacy and safety outcomes we pooled data from the four classical design RCTs. Since the FREEDOM trial differed significantly in trial methodology it was considered separately alongside the pooled analysis.
Efficacy outcomes Figure 1 shows the pooled weekly mean pain scores for the four classical design RCTs. Baseline pain scores were comparable across treatment groups with a baseline mean weekly pain score of about 7/10 on a numerical rating scale, indicating severe pain. Over time mean pain levels decreased for all treatments. They had reached a steady state by Week 6. When compared with placebo, 450 and 600 mg/day pregabalin led to a statistically significant reduction in pain scores for all time-points during Weeks 1-14; 300 mg resulted in a significant reduction in pain scores for most time-points apart from Weeks 8, 10 and 11. Table 2 illustrates dichotomous efficacy outcomes from our pooled analysis of the four classical design RCTs. Pregabalin at doses of 300-600 mg/day brought about a significant increase in the number of 30% responders and 50% responders. The only significant differences between doses were for 50% responders at 450 or 600 mg compared with 150 mg. Only one trial had a 150 mg group (trial 105). This dose did not result in a significant increase in the number of 50% responders; 30% responders were not reported. About 40% of patients taking pregabalin 300-600 mg/day had 'much' or 'very much' improvement in PGIC, compared with 27% with placebo. For these dichotomous efficacy outcomes, the NNTs for one person to benefit compared with placebo over the dose range 300-600 mg/day of pregabalin were 9-14 for 300 mg, 7-10 for 450 mg and 8-11 for 600 mg ( Table 2) . Discontinuations due to lack of efficacy were lower with 300-600 mg pregabalin (2-4%) than placebo (9-10%), with numbers needed to prevent one person discontinuing of 15-18. Continuous efficacy outcomes are shown in Table 3 . The FIQ total score, MAF global index, HADS subscale scores, MOS-sleep scores, sleep quality scores and the majority of the individual domains of SF-36 were all significantly reduced by at least one dose of pregabalin. In some cases, the statistical significance was greater with 450 mg than with 600 mg. This may have to do with patient numbers, however, as only three of the four classical design trials had 600 mg/day pregabalin groups (trials 1056, 1077 and 1100) but all four had 300 and 450 mg groups (Table 1) .
In the FREEDOM trial, 54% of those assigned to open-label treatment had at least 50% pain relief on a NNT becomes NNTp (number needed to treat to prevent one event) when event rate is lower with pregabalin than with placebo. NNT/NNTp was not calculated when the relative benefit or risk included 1 and was not statistically significant. Statistically significant differences between doses for at least 50% pain relief were www.rheumatology.oxfordjournals.org VAS over baseline and a PGIC of 'much' or 'very much' improved and so were able to enter the double-blind phase. During the double-blind treatment phase, the primary end-point, time to loss of therapeutic response, was significantly longer for patients receiving pregabalin than for the placebo group. For pregabalin, only 90/279 (32%) experienced loss of therapeutic response, compared with 174/287 (61%) with placebo. The NNT to prevent one patient experiencing a loss of treatment response over a period of 26 weeks was 3.5 (95% CI 2.8, 4.9). All secondary efficacy end-points (PGIC, FIQ total score, 9-item MOS sleep problems index, MAF global index and all eight SF-36 subscales) showed significantly greater time to loss of therapeutic response for pregabalin compared with placebo.
Adverse event outcomes Table 4 shows details of the pooled analysis. For the adverse event outcomes of patients experiencing at least one adverse event, somnolence, dizziness, >7% weight gain and discontinuations because of adverse events, pregabalin doses of 5300 mg generated more adverse events than placebo. For a number of these outcomes (at least one adverse event, dizziness and discontinuation due to adverse events as well as all-cause discontinuations) there was a significant dose-response relationship. For other adverse events outcomes (somnolence, nausea and weight gain) there was no significant dose dependence. There was no significant difference between pregabalin and placebo in the rate of serious adverse events ($2% in each case). No deaths were reported in the four classical design RCTs.
In During the open-label phase, serious adverse events occurred in 8/1051 patients (0.8%). Two patients died during the FREEDOM trial: one receiving placebo died during the double-blind phase because of a pulmonary embolism, the other receiving pregabalin died of lobar pneumonia 28 days after the end of the double-blind phase. Study investigators did not consider these deaths as associated with study drug.
Discussion
All the patients studied fulfilled the pre-determined diagnostic criteria and comprised a defined group of patients with a significant chronic pain syndrome named as FM. In *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. NNH becomes NNTp (number needed to treat to prevent one event) when event rate is lower with pregabalin than with placebo. NNH/NNTp was not calculated when the relative benefit or risk included 1 and was not statistically significant. Statistically significant differences between doses for at least 50% pain relief were a P = 0.0065 for 150 vs 450 mg; b P = 0.0031 for 150 vs 600 mg; c P = 0.038 for 300 vs 600 mg; d P = 0.048 for 150 vs 300 mg; e P < 0.00006 for 150 vs 450 mg; f P = 0.000067 for 300 vs 450 mg; g P < 0.00006 for 150 vs 600 mg; h P < 0.00006 for 300 vs 600 mg; i P = 0.019 for 150 vs 450 mg; j P < 0.00006 for 150 vs 600 mg; k P = 0.00014 for 300 vs 600 mg; l P = 0.015 for 450 vs 600 mg; m P = 0.021 for 150 vs 600 mg; n P = 0.026 for 300 vs 600 mg; P = 0.034 for 450 vs 600 mg.
www.rheumatology.oxfordjournals.org
711
Pregabalin in FM the 19 years since the ACR defined diagnostic criteria for FM several thousand papers have studied the same diagnostic group. FM matters to patients. At baseline the pain in FM patients was about 7/10 on the verbal rating scale (Fig. 1) . This is severe pain, comparable with that seen in untreated OA [31] . Other systematic reviews of treatments for FM have recently been published [11, 12 and 32] . This article provides an account of pregabalin in FM on the basis of high-quality trials involving more patients than any other systematic review. As with previous systematic reviews on chronic pain from company clinical trial reports [33] , these very detailed reports contain information on a variety of outcomes-not only pain scales but also, for example, data on total and component scores from FIQ, MOS-sleep scale, sleep quality score, SF-36, MAF and HADS-and therefore, allow a more complete assessment of a range of outcome measurements than published reports, which are by necessity more concise and would not normally have the space to report on all of the aforementioned outcomes or do so in less detail.
Efficacy of pregabalin in FM
Pregabalin significantly improved pain and other symptoms of FM. A dose-response relationship could only be shown for 50% responders, a measurement constituting substantial improvement [21] . The pregabalin dose-response relationship for efficacy in FM was not as striking as that seen in other conditions [19, 34, 35] . At least 50% pain relief was obtained by only 24% of the people taking pregabalin at the higher doses (450-600 mg). While applicable only to a minority, this is an important outcome for those people who achieve it.
In other painful conditions, like OA and classic neuropathic pain, only a minority of patients have a substantial response [12, 36, 37] . The absence of a clear doseresponse relationship for all but one of the efficacy outcomes may be due to the low response rates in classical design trials.
Adverse events associated with pregabalin
Even though individual trials may not have been powered to detect significances in adverse events between groups, the large number of patients in this meta-analysis and the consistency of adverse event reporting between trials allow us to draw conclusions about adverse events with a high level of confidence.
Most people in pregabalin and placebo groups experienced adverse events. This is not surprising considering the range of symptoms associated with FM, some of which may be reported as adverse events in a clinical trial. The rate of serious adverse events was roughly similar, and low with pregabalin and placebo. Some adverse events such as weight gain, somnolence and dizziness are typical of pregabalin and occurred more commonly with pregabalin, as reported previously [19] . For dizziness, clear dose dependence was apparent over the range 150-600 mg, more striking perhaps than that for efficacy.
Effect of trial design on efficacy estimates
Of the four classical design RCTs, three studies (trials 1056, 1077 and 1100) used non-enriched enrolment. One study (trial 105) used partial enriched enrolment. The FREEDOM trial fulfilled criteria for complete enriched enrolment. In the four trials of classical design, $40% of patients taking pregabalin 300-600 mg/day had a PGIC rating of 'much' or 'very much' improvement. In the FREEDOM trial, 54% of those patients who entered the open-label phase had at least 50% pain relief on a VAS over baseline and a PGIC of 'much' or 'very much' improved and so continued into the double-blind phase. Comparing these two response rates, the larger size of effect observed in the FREEDOM trial (54%) was obtained during an open-label phase, without a placebo group, and in patients titrated to an optimal dose of pregabalin. The smaller effect size ($40%) occurred in double-blind, placebo-controlled trials, in which patients were randomized to different doses of pregabalin irrespective of which dose might suit them best. Given these differences in trial design, the difference in response rates was not surprising.
It is interesting to compare results obtained from the four classically designed trials that lasted up to 14 weeks, and from the enriched enrolment randomized withdrawal FREEDOM trial, lasting 32 weeks in total, with a 26-week withdrawal phase. Differences in dose, duration and in outcome preclude direct comparison, especially as we have at least 30 and 50% pain reduction as outcomes in the classical trials, and a requirement to meet at least 50% pain reduction twice over 4-6 weeks, and then not have pain worse than <30% reduction after randomization and up to 26 weeks in FREEDOM. This is the first large test of an enriched enrolment randomized withdrawal design in a painful condition allowing comparison with classical design [20] , and it provided credible efficacy results. While NNTs in the range 7-10 were obtained for 450 and 600 mg at the end of trial with classic designs, the NNT for loss of therapeutic response was 3.5 in FREEDOM. Allowing that half of enrolled patients were not responders by 6 weeks, the NNT in FREEDOM is about 7.2 if an intention-to-treat approach of a classic design were used. The fraction of the FM population obtaining moderate or substantial benefit [21] was about the same in both cases. As has been argued previously [38] , the open-label phase in FREEDOM made no substantial difference to the proportion of patients benefiting from pregabalin compared with conventionally designed trials, supporting enriched enrolment randomized withdrawal as a trial design.
Moreover, FREEDOM provided two additional pieces of information. It showed that a 6-week trial of pregabalin was sufficient to identify responders, enabling an early decision about lack of response and choice of alternative therapy. It also demonstrated sustained benefit over 26 weeks, with loss of therapeutic response occurring soon after randomization, and being uncommon after 14 weeks. This argues that classical trials of 12-14 weeks' duration provide a satisfactory basis to judge continued efficacy.
Limitations of the meta-analysis
While the trials included were of adequate reporting quality to avoid bias, had sufficient patients to avoid inaccuracies due to the random play of chance, and were valid-being of long duration and capturing a wide range of efficacy and adverse event outcomes-the largest limitation remains how to interpret these data in terms of the individual patient. It is possible, for instance, to provide estimates of the likelihood of achieving moderate or substantial pain relief with pregabalin for over a period of 12 weeks (one in three and one in four, respectively). Pregabalin also carries a one in five chance of somnolence and one in two chance of dizziness.
While continuous outcomes like FIQ were significantly improved with pregabalin, the magnitude of the average change between pregabalin and placebo is difficult to understand or explain to others. While a change in FIQ from baseline of 14% is claimed as the minimal average difference to be clinically relevant [the minimally important clinical difference (MCID)] [39] , this does not help interpret an 8% decrease on average compared with placebo at the end of the trial (though pregabalin groups did have average FIQ change from baseline of the order of 20%, which is above the MCID). End-of-trial average FIQ total scores indicating moderate impairment include patients with mild and severe impairment.
A meta-analysis based on clinical trial reports that give group average results is limited in this respect. To make trial data more relevant would require individual patient analysis showing that patients who benefited on one outcome, like pain, showed relevant clinical improvements in all or many of the major outcomes, like FIQ. A different analysis found a high degree of correlation between FIQ total score and average daily pain score [39] .
Comparison of pregabalin with other treatments for FM-implications for clinical practice and future research A number of treatments have been advocated for FM and recent reviews and guidelines indeed recommend a multidisciplinary and integrated approach involving interventions as diverse as heated pool treatment, exercise, cognitive behavioural therapy and pharmacotherapy with agents ranging from tramadol to anti depressants and alpha 2 -delta ligands [9, 40] . The right combination of treatments needs to be tailored to the needs of the individual patient.
Despite a number of studies conducted to investigate FM treatments over the years, few have been performed in large numbers and reported results in a format that allows for meaningful comparisons of outcomes indicating substantial improvement, such as at least 50% pain relief. Duloxetine in FM has been the subject of a recent meta-analysis, and combination treatment with tramadol and paracetamol has been investigated in a large RCT [12, 41] . These interventions are compared with pregabalin in Table 5 . Even though responder rates in active treatment groups and placebo groups differ, the relative benefits are remarkably similar. Comparing NNTs, both the paracetamol and tramadol combination and duloxetine seem slightly more effective than pregabalin. However, lower patient numbers, especially in the case of tramadol and paracetamol, mean that there is more uncertainty about the magnitude of effect. Comparing duloxetine and tramadol/paracetamol with pregabalin using the z-test [30] , no significant differences were found.
The use of amitriptyline in FM was investigated in a recent systematic review [42] . While 50 mg/day amitriptyline did not have a demonstrable benefit, 25 mg/day was significantly better than placebo for patient global assessment, pain, sleep and fatigue in some trials. Why lower dose amitriptyline appears to work better than higher dose, and how the size of effect compares with pregabalin with regard to outcomes indicating substantial clinical improvement, is unclear, but may simply be an artefact of small trials of poor quality and short duration. A number of other agents, including anti depressants and cyclobenzaprine are effective for FM [11, 32] , but again it is unclear at present how they compare quantitatively with pregabalin.
There is no clear evidence of superiority of one drug over another in FM at present, because the drugs we have produce a substantial benefit in only a minority of patients. We do not know whether patients who respond to one would also respond to another. On average a number of drugs seem to be roughly equally effective, but as with neuropathic pain, individual patients may respond to one drug better than another. Therefore, various treatment options should be made available to patients.
The nature of FM complicates matters further. FM can manifest differently in different patients. At present, the clinical challenge in FM lies in finding the right combination of treatments, pharmacological and/or non-pharmacological, best suited to individual patients. This will in part be empirical, at least until sub-types of FM with distinct pathophysiology can be differentiated, and drug choice informed by mechanistic or genetic determinants. Both then and now, there will be a need for tailored treatment for individual patients. In future, trial designs that stratify patients according to baseline symptomatology, offer tailored treatment regimens based upon the range and extent of baseline symptoms, and compare different interventions against each other rather than only against placebo, may offer more rational solutions. Outcomes investigated in future trials should relate to substantial improvements, such as at least 50% pain relief. The low rates of responders in classical design trials suggest that only a proportion of patients with FM are helped by pregabalin. To more clearly demonstrate a therapeutic effect and a doseresponse relationship, trials with enriched enrolment designs may be better suited.
Rheumatology key messages
. Pregabalin is highly effective in some patients. . The effect size is similar to other interventions. . Enriched enrolment randomized withdrawal trials produce similar results to classical trial designs.
